is a partner in the Corporate & Securities Practice Group and co-head of the North American Healthcare & Life Sciences Industry Group. Randy structures and negotiates complex collaborations, mergers and acquisitions, divestitures, joint ventures, and corporate partnering and licensing transactions, as well as equity investments and royalty monetisation transactions for clients ranging from biotech startups to multinational pharmaceutical companies. He advises private equity, venture capital, and investment banking firms. Randy counsels on alternative ﬁnancing arrangements such as royalty monetisations. He also handles technical contractual arrangements for drug discovery, development, manufacturing and supply, marketing and co-promotion, and outsourcing in the life sciences industry. Randy's wealth of global life sciences experience draws many invitations to speak at industry events worldwide. He has spoken on such topics as mergers and acquisitions, strategic alliances, and licensing and collaboration transactions in the United States at Allicense, BIO and LES annual meetings, in Canada at BIOMedex, and in China at BIO Forum, as well as at other life sciences–related conferences. He has also been a guest lecturer at the Rutgers Business School MBA Biotechnology Commercialization Concentration.